> Detailanzeige

Kroidl, Inge; Winter, Simon; Rubio-Acero, Raquel; Bakuli, Abhishek; Geldmacher, Christof; Eser, Tabea M.; Déak, Flora; Horn, Sacha; Zielke, Anna; Ahmed, Mohamed I. M.; Diepers, Paulina; Guggenbühl, Jessica; Frese, Jonathan; Bruger, Jan; Puchinger, Kerstin; Reich, Jakob; Falk, Philine; Markgraf, Alisa; Fensterseifer, Heike; Paunovic, Ivana; Thomschke, Angelika; Pritsch, Michael; Riess, Friedrich; Saathoff, Elmar; [...]

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison
  • Beteiligte: Kroidl, Inge; Winter, Simon; Rubio-Acero, Raquel; Bakuli, Abhishek; Geldmacher, Christof; Eser, Tabea M.; Déak, Flora; Horn, Sacha; Zielke, Anna; Ahmed, Mohamed I. M.; Diepers, Paulina; Guggenbühl, Jessica; Frese, Jonathan; Bruger, Jan; Puchinger, Kerstin; Reich, Jakob; Falk, Philine; Markgraf, Alisa; Fensterseifer, Heike; Paunovic, Ivana; Thomschke, Angelika; Pritsch, Michael; Riess, Friedrich; Saathoff, Elmar; [...]
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: Virology Journal
  • Sprache: Englisch
  • DOI: 10.1186/s12985-023-02167-z
  • ISSN: 1743-422X
  • Schlagwörter: Infectious Diseases ; Virology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU).</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 surrogate virus neutralization. Both cohorts were evaluated using the Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and the Roche Elecsys Anti-SARS-CoV-2 anti-S1 assay.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>In SARS-CoV-2-convalesce subjects, the BAU-sero-responses of Euroimmun Anti-SARS-CoV-2-ELISA anti-S1 IgG and Roche Elecsys Anti-SARS-CoV-2 anti-S1 peaked both at 47 (43–51) days, the first assay followed by a slow decay thereafter (&gt; 208 days), while the second assay not presenting any decay within one year. Both assay values in BAUs are only equivalent a few months after infection, elsewhere correction factors up to 10 are necessary. In contrast, in infection-naive vaccinees the assays perform similarly.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The results of our study suggest that the establishment of a protective correlate or vaccination booster recommendation based on different assays, although BAU-standardised, is still challenging. At the moment the characteristics of the available assays used are not related, and the BAU-standardisation is unable to correct for that.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang